CoChat

Endometrial Intracrinology: Oestrogens, Androgens and Endometrial Disorders

Open access
Gibson, Douglas A., Simitsidellis, Ioannis, Collins, Frances, Saunders, Philippa T.K. · 2018 · International Journal of Molecular Sciences

Published version of a preprint

The DOI matches its Crossref record; 115 of the 120 references it cites were found in a registry or an index; 45 of the 130 sources its claims cite were checked for support.

Abstract

Peripheral tissue metabolism of steroids (intracrinology) is now accepted as a key way in which tissues, such as the endometrium, can utilise inactive steroids present in the blood to respond to local physiological demands and ‘fine-tune’ the activation or inhibition of steroid hormone receptor-dependent processes. Expression of enzymes that play a critical role in the activation and inactivation of bioactive oestrogens (E1, E2) and androgens (A4, T, DHT), as well as expression of steroid hormone receptors, has been detected in endometrial tissues and cells recovered during the menstrual cycle. There is robust evidence that increased expression of aromatase is important for creating a local microenvironment that can support a pregnancy. Measurement of intra-tissue concentrations of steroids using liquid chromatography–tandem mass spectrometry has been important in advancing our understanding of a role for androgens in the endometrium, acting both as active ligands for the androgen receptor and as substrates for oestrogen biosynthesis. The emergence of intracrinology, associated with disordered expression of key enzymes such as aromatase, in the aetiology of common women’s health disorders such as endometriosis and endometrial cancer has prompted renewed interest in the development of drugs targeting these pathways, opening up new opportunities for targeted therapies and precision medicine.

Overview

CoChat Summary

TL;DR

This review argues that endometrial intracrinology—local activation and inactivation of oestrogens and androgens—is central to normal endometrial function and to disorders such as endometriosis and endometrial cancer. It synthesizes evidence on steroidogenic enzymes, receptor expression, LC-MS/MS tissue steroid measurements, and emerging intracrine-targeted therapies.

Key findings

  • Local endometrial steroid concentrations can diverge from serum: LC-MS/MS studies found higher tissue oestrogens than in circulation and increased secretory-phase E2; intra-tissue DHEA was significantly higher than serum in secretory phase, whereas A4 and T were significantly lower in endometrial tissue than serum and not cycle-phase dependent.
  • Endometriotic lesions show heterogeneous intracrine steroid production: in proliferative phase, E2 concentrations were approximately 3430 pg/mL in ovarian lesions (endometrioma) versus 238 pg/mL in peritoneal lesions; lesion testosterone exceeded blood, with elevated CYP11A1, CYP17A1 and HSD3B2, lower HSD17B2, and higher HSD17B6 and CYP19A1.
  • In endometrial cancer, aromatase and 17βHSD1 expression correlated with poor prognosis; EC tissues had an 8-fold elevation in DHT versus normal endometrium; 5αR1 expression in 65% of samples positively correlated with histological grade, and women immunonegative for both AR and 5αR1 had poorer prognosis.
  • Therapeutic targeting is advancing: intravaginal DHEA/prasterone showed local benefit without peripheral serum E2 changes; aromatase inhibitors are considered for postmenopausal endometriosis pain; AKR1C3 inhibitor BAY 1128688 completed phase I in 2016 with phase II underway; 17βHSD1 inhibitor FOR-6219 began phase Ia in July 2018; STS inhibitor STX64/Irosustat did not improve survival in a phase 2 endometrial cancer trial.

Methods

  • Narrative review; PubMed and Scopus were searched on 4 May 2018 using terms including intracrinology, endometrium, aromatase, sulfatase and HSD. Reported counts included intracrinology 167 references in Scopus; intracrinology and endometrium 11 PubMed/21 Scopus; aromatase and endometrium 398; aromatase and endometrium and cancer and human 135; sulfatase and endometrium 84; HSD and endometrium 131.
  • Evidence was synthesized from human endometrial tissues and cells, mouse models, LC-MS/MS steroid profiling, immunohistochemistry/qRT-PCR, in vitro decidualisation studies, and clinical trial reports; no formal systematic review or meta-analysis is described.

Limitations

  • Stated in the paper: whole endometrial tissue homogenates cannot quantify contributions of specific cellular compartments; lesion types differ in local steroid concentrations and steroid-metabolising enzyme expression; no study has identified definitive de novo steroidogenesis from normal endometrial tissue; further studies are needed on cell cross-talk, non-coding RNAs, and therapeutic evaluation.
  • Evident from the text: this is a narrative review with a non-systematic search limited to PubMed/Scopus on one date and no formal quality appraisal; many cited therapeutic findings are early-phase, awaited, or from cell/animal models.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3390/ijms19103276

Cites

115 of 115 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Histology of the human endometrium during the normal cycle. Full-thickness endometrial biopsies from hysterectomy specimens stained with haematoxylin and eosin. (A) Proliferative phase: note the presence of long curving glands (G) and some stromal oedema [23]. (B) Secretory phase: note the prominent glands (G), which have a dilated lumen and an irregular outer border stretching down into the basal compartment [24]. In the luminal (functional layer) immune cells are readily detected (most of these are likely to be macrophages and uterine natural killer (uNK) cells [17,19]), as are areas of decidualised fibroblasts (DEC) close to arterioles.
Figure 1 Histology of the human endometrium during the normal cycle. Full-thickness endometrial biopsies from hysterectomy specimens stained with haematoxylin and eosin. (A) Proliferative phase: note the presence of long curving glands (G) and some stromal oedema [23]. (B) Secretory phase: note the prominent glands (G), which have a dilated lumen and an irregular outer border stretching down into the basal compartment [24]. In the luminal (functional layer) immune cells are readily detected (most of these are likely to be macrophages and uterine natural killer (uNK) cells [17,19]), as are areas of decidualised fibroblasts (DEC) close to arterioles.CC BY · PubMed Central
Figure 2 Expression of AKR1C3 in human endometrial stromal fibroblasts is increased in response to a decidualisation stimulus resulting in increased biosynthesis and secretion of testosterone. Based on a figure published in [43] under a CC-BY licence: concentrations of T were determined using an ELISA on days 4 or 8 of the experiment. Immunohistochemistry was determined on day 4 of experiment; AKR1C3 (red stain) Sytox Green nuclear stain (green), no primary antibody negative control (inset) (** p < 0.01).
Figure 2 Expression of AKR1C3 in human endometrial stromal fibroblasts is increased in response to a decidualisation stimulus resulting in increased biosynthesis and secretion of testosterone. Based on a figure published in [43] under a CC-BY licence: concentrations of T were determined using an ELISA on days 4 or 8 of the experiment. Immunohistochemistry was determined on day 4 of experiment; AKR1C3 (red stain) Sytox Green nuclear stain (green), no primary antibody negative control (inset) (** p < 0.01).CC BY · PubMed Central
Figure 3 In vitro decidualisation of endometrial stromal fibroblasts results in upregulation of aromatase protein expression (green). Based on data reported in [13]. ESC—primary endometrial stromal fibroblasts; positive control (+) was a protein extract from human placenta, aromatase protein 58kDa. Nuclear counterstain DAPI (blue); Aromatase (green); B-Actin loading control (red).
Figure 3 In vitro decidualisation of endometrial stromal fibroblasts results in upregulation of aromatase protein expression (green). Based on data reported in [13]. ESC—primary endometrial stromal fibroblasts; positive control (+) was a protein extract from human placenta, aromatase protein 58kDa. Nuclear counterstain DAPI (blue); Aromatase (green); B-Actin loading control (red).CC BY · PubMed Central

Verification

Claims the paper makes

38 Valid · 0 Not valid · 52 Not checked · 11 Own results and interpretations

65 more claims · 17 with their cited sources checked

Create a free account to see all 101 claims and to verify the 9 references still open.

See all claims — free account
  • It may state two separate claims as one. 31

Create a free account to see these claims.

Citations

Cites

Cited by

See all 70

Metadata

Authors
Gibson, D. A., Simitsidellis, I., Collins, F., & Saunders, P. T. K.
Affiliations
Centre for Inflammation Research (GB)
Corresponding author
Saunders, Philippa T.K.
Venue
International Journal of Molecular Sciences
Publisher
MDPI AG
Published
2018-10-22
Volume
19
Issue
10
Pages
3276
ISSN
1422-0067 (ISSN-L)
OpenAlex
W2894914503
Cited by
70
References
120
Citations by year
2026: 8 · 2025: 5 · 2024: 8 · 2023: 9 · 2022: 13 · 2021: 10 · 2020: 10 · 2019: 6 · 2018: 1
FWCI
0.93
Type
journal article
Language
en
Open access
Locations
  • International Journal of Molecular Sciences (publishedVersion, cc-by)
  • Preprints.org (acceptedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Edinburgh Research Explorer (University of Edinburgh) (submittedVersion, other-oa)
Funders
Medical Research Council (MR/N024524/1, MR/P00265X/1)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
  • Health Sciences › Medicine › Obstetrics and Gynecology › Endometrial and Cervical Cancer Treatments
  • Physical Sciences › Chemistry › Organic Chemistry › Steroid Chemistry and Biochemistry
Keywords
steroid hormone metabolism, aromatase, estrogen, androgens, endometrium, menstrual cycle, androgen receptor, estrogen synthesis, endometriosis, endometrial cancer, steroid hormone receptors
MeSH terms
Androgens, Dehydroepiandrosterone, Endometrium, Estrogens, Female, Humans, Testosterone, Uterine Diseases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.